{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:40:18Z","timestamp":1790804418202,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11239-020-02100-z","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T21:11:24Z","timestamp":1586293884000},"page":"995-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study"],"prefix":"10.1007","volume":"50","author":[{"given":"Micha\u00ebl","family":"Levraut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Drappier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Queyrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Raynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-3169","authenticated-orcid":false,"given":"Nihal","family":"Martis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2100_CR1","first-page":"344","volume":"3","author":"MA Elliott","year":"2004","unstructured":"Elliott MA, Tefferi A (2004) Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Current Hematology Reports 3:344\u2013351","journal-title":"Current Hematology Reports"},{"key":"2100_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MBC.0b013e328304e0a9","volume":"19","author":"SG Xavier","year":"2008","unstructured":"Xavier SG, Gadelha T, Schaffel R, Britto L, Pimenta G, Ribeiro DD et al (2008) Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis. Blood Coagul Fibrinolysis 19:468\u2013469. https:\/\/doi.org\/10.1097\/MBC.0b013e328304e0a9","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2100_CR3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s10620-009-0933-y","volume":"55","author":"SG Xavier","year":"2010","unstructured":"Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM et al (2010) JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci 55:1770\u20131777. https:\/\/doi.org\/10.1007\/s10620-009-0933-y","journal-title":"Dig Dis Sci"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1751-553X.2010.01275.x","volume":"33","author":"SG Xavier","year":"2011","unstructured":"Xavier SG, Gadelha T, Rezende SM, Zalcberg IR, Spector N (2011) JAK2V617F mutation in patients with thrombosis: to screen or not to screen? Int J Lab Hematol 33:117\u2013124. https:\/\/doi.org\/10.1111\/j.1751-553X.2010.01275.x","journal-title":"Int J Lab Hematol"},{"key":"2100_CR5","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120:5128\u20135133. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"key":"2100_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet 365:1054\u20131061. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9","journal-title":"The Lancet"},{"key":"2100_CR7","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A et al (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer Journal 5:e369\u2013e369. https:\/\/doi.org\/10.1038\/bcj.2015.94","journal-title":"Blood Cancer Journal"},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","volume":"5","author":"V De Stefano","year":"2007","unstructured":"De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P et al (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5:708\u2013714. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02424.x","journal-title":"J Thromb Haemost"},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","volume":"5","author":"S Regina","year":"2007","unstructured":"Regina S, Herault O, D\u2019Alteroche L, Binet C, Gruel Y (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5:859\u2013861. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02384.x","journal-title":"J Thromb Haemost"},{"key":"2100_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","volume":"5","author":"D Colaizzo","year":"2007","unstructured":"Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA et al (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5:55\u201361. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02277.x","journal-title":"J Thromb Haemost"},{"key":"2100_CR11","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HLA, Leebeek FWG (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921\u20134928. https:\/\/doi.org\/10.1182\/blood-2011-09-376517","journal-title":"Blood"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","volume":"113","author":"F Dentali","year":"2009","unstructured":"Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M et al (2009) JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113:5617\u20135623. https:\/\/doi.org\/10.1182\/blood-2008-12-196014","journal-title":"Blood"},{"key":"2100_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3324\/haematol.2010.033191","volume":"96","author":"C Nielsen","year":"2011","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96:450\u2013453. https:\/\/doi.org\/10.3324\/haematol.2010.033191","journal-title":"Haematologica"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","volume":"99","author":"C Nielsen","year":"2014","unstructured":"Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS (2014) JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 99:1448\u20131455. https:\/\/doi.org\/10.3324\/haematol.2014.107631","journal-title":"Haematologica"},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"2100_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jmv.2009.02.005","volume":"34","author":"G Pernod","year":"2009","unstructured":"Pernod G, Biron-Andreani C, Morange P-E, Boehlen F, Constans J, Couturaud F et al (2009) Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 34:156\u2013203","journal-title":"J Mal Vasc"},{"key":"2100_CR17","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jth.13336","volume":"14","author":"C Kearon","year":"2016","unstructured":"Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing G-J, Kyrle PA et al (2016) Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 14:1480\u20131483. https:\/\/doi.org\/10.1111\/jth.13336","journal-title":"J Thromb Haemost"},{"key":"2100_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jmoldx.2016.08.006","volume":"19","author":"F Usseglio","year":"2017","unstructured":"Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia. J Mol Diagn 19:92\u201398. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.08.006","journal-title":"J Mol Diagn"},{"issue":"2","key":"2100_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V De Stefano","year":"2009","unstructured":"De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al (2009) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85(2):97\u2013100.","journal-title":"Am J Hematol"},{"key":"2100_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","volume":"121","author":"M De Grandis","year":"2013","unstructured":"De Grandis M, Cambot M, Wautier M-P, Cassinat B, Chomienne C, Colin Y et al (2013) JAK2V617F activates Lu\/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1\/Akt pathway. Blood 121:658\u2013665. https:\/\/doi.org\/10.1182\/blood-2012-07-440487","journal-title":"Blood"},{"key":"2100_CR21","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446\u20132452. https:\/\/doi.org\/10.1182\/blood-2006-08-042515","journal-title":"Blood"},{"key":"2100_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","volume":"114","author":"T Barbui","year":"2009","unstructured":"Barbui T, Carobbio A, Rambaldi A, Finazzi G (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114:759\u2013763. https:\/\/doi.org\/10.1182\/blood-2009-02-206797","journal-title":"Blood"},{"key":"2100_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","volume":"33","author":"A Falanga","year":"2005","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T (2005) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 33:523\u2013530. https:\/\/doi.org\/10.1016\/j.exphem.2005.01.015","journal-title":"Exp Hematol"},{"key":"2100_CR24","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","volume":"117","author":"L Teofili","year":"2011","unstructured":"Teofili L, Martini M, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L et al (2011) Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 117:2700\u20132707. https:\/\/doi.org\/10.1182\/blood-2010-07-297598","journal-title":"Blood"},{"key":"2100_CR25","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","volume":"113","author":"S Sozer","year":"2009","unstructured":"Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R (2009) The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113:5246\u20135249. https:\/\/doi.org\/10.1182\/blood-2008-11-191544","journal-title":"Blood"},{"key":"2100_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","volume":"121","author":"V Rosti","year":"2013","unstructured":"Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L et al (2013) Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 121:360\u2013368. https:\/\/doi.org\/10.1182\/blood-2012-01-404889","journal-title":"Blood"},{"key":"2100_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.2018.195321","volume":"104","author":"A Guy","year":"2019","unstructured":"Guy A, Gourdou-Latyszenok V, Le Lay N, Peghaire C, Kilani B, Dias JV et al (2019) Vascular endothelial cell expression of JAK2 V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica 104:70\u201381. https:\/\/doi.org\/10.3324\/haematol.2018.195321","journal-title":"Haematologica"},{"key":"2100_CR28","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1055\/s-0038-1673614","volume":"118","author":"Y Feng","year":"2018","unstructured":"Feng Y, Yu M, Zhu F, Zhang S, Ding P, Wang M (2018) IL-9 promotes the development of deep venous thrombosis by facilitating platelet function. Thromb Haemost 118:1885\u20131894. https:\/\/doi.org\/10.1055\/s-0038-1673614","journal-title":"Thromb Haemost"},{"key":"2100_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.niox.2007.01.001","volume":"16","author":"VP Cokic","year":"2007","unstructured":"Cokic VP, Beleslin-Cokic BB, Noguchi CT, Schechter AN (2007) Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity. Nitric Oxide 16:371\u2013378. https:\/\/doi.org\/10.1016\/j.niox.2007.01.001","journal-title":"Nitric Oxide"},{"key":"2100_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood-2005-11-4454","volume":"108","author":"VP Cokic","year":"2006","unstructured":"Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN (2006) Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 108:184\u2013191. https:\/\/doi.org\/10.1182\/blood-2005-11-4454","journal-title":"Blood"},{"key":"2100_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4065\/83.4.457","volume":"83","author":"A Pardanani","year":"2008","unstructured":"Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK et al (2008) JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 83:457\u2013459. https:\/\/doi.org\/10.4065\/83.4.457","journal-title":"Mayo Clin Proc"},{"key":"2100_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00277-016-2853-1","volume":"96","author":"J-C Ianotto","year":"2017","unstructured":"Ianotto J-C, Chauveau A, Mottier D, Ugo V, Berthou C, Lippert E et al (2017) JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort. Ann Hematol 96:383\u2013386. https:\/\/doi.org\/10.1007\/s00277-016-2853-1","journal-title":"Ann Hematol"},{"key":"2100_CR33","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","volume":"20","author":"P Sidon","year":"2006","unstructured":"Sidon P, El Housni H, Dessars B, Heimann P (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20:1622. https:\/\/doi.org\/10.1038\/sj.leu.2404292","journal-title":"Leukemia"},{"key":"2100_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","volume":"135","author":"M Borowczyk","year":"2015","unstructured":"Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopyd\u0142owska A et al (2015) The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res 135:272\u2013280. https:\/\/doi.org\/10.1016\/j.thromres.2014.11.006","journal-title":"Thromb Res"},{"key":"2100_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jns.2012.09.012","volume":"323","author":"T De","year":"2012","unstructured":"De T, Prabhakar P, Nagaraja D, Christopher R (2012) Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders. J Neurol Sci 323:178\u2013182. https:\/\/doi.org\/10.1016\/j.jns.2012.09.012","journal-title":"J Neurol Sci"},{"key":"2100_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000471891","volume":"44","author":"M Lamy","year":"2017","unstructured":"Lamy M, Palazzo P, Agius P, Chomel JC, Ciron J, Berthomet A et al (2017) Should we screen for janus kinase 2 V617F mutation in cerebral venous thrombosis? Cerebrovasc Dis 44:97\u2013104. https:\/\/doi.org\/10.1159\/000471891","journal-title":"Cerebrovasc Dis"},{"key":"2100_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/j.1538-7836.2012.04719.x","volume":"10","author":"SM Passamonti","year":"2012","unstructured":"Passamonti SM, Biguzzi E, Cazzola M, Franchi F, Gianniello F, Bucciarelli P et al (2012) The JAK2 V617F mutation in patients with cerebral venous thrombosis. J Thromb Haemost 10:998\u20131003. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04719.x","journal-title":"J Thromb Haemost"},{"key":"2100_CR38","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1111\/jth.13791","volume":"15","author":"A Delluc","year":"2017","unstructured":"Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M (2017) Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 15:2076\u20132079. https:\/\/doi.org\/10.1111\/jth.13791","journal-title":"J Thromb Haemost"},{"key":"2100_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s11239-015-1316-1","volume":"41","author":"SM Stevens","year":"2016","unstructured":"Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M et al (2016) Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 41:154\u2013164. https:\/\/doi.org\/10.1007\/s11239-015-1316-1","journal-title":"J Thromb Thrombolysis"},{"key":"2100_CR40","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMc1713797","volume":"377","author":"JM Connors","year":"2017","unstructured":"Connors JM (2017) Thrombophilia testing and venous thrombosis. N Engl J Med 377:2297\u20132298. https:\/\/doi.org\/10.1056\/NEJMc1713797","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-020-02100-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-020-02100-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:20:02Z","timestamp":1722702002000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-020-02100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1007\/s11239-020-02100-z","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]},"assertion":[{"value":"7 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no personal conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. According to current regulations, informed consent was systematically required prior to performing genetic tests. Due to the retrospective design of the study, informed consent from patients was not required for their inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}